{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T08:58:03Z","timestamp":1764925083618,"version":"3.46.0"},"reference-count":31,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2025.15385","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T12:57:49Z","timestamp":1762952269000},"page":"1-5","source":"Crossref","is-referenced-by-count":0,"title":["Remarkable response to Osimertinib plus Gumarontinib for EGFR mutation and concomitant MET exon 14 skipping in a patient with lung adenocarcinoma: A case report"],"prefix":"10.3892","volume":"31","author":[{"given":"Xuquan","family":"Jing","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong 250117, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong 250117, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuangqing","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong 250117, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyang","family":"Zhai","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong 250117, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong 250117, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"key":"key20251205105345_b1-ol-31-1-15385","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1002\/cncr.35128","article-title":"Lung cancer statistics, 2023","volume":"130","author":"Kratzer","year":"2024","journal-title":"Cancer"},{"key":"key20251205105345_b2-ol-31-1-15385","doi-asserted-by":"publisher","first-page":"e27591","DOI":"10.1016\/j.heliyon.2024.e27591","article-title":"Targeted next-generation sequencing of 491 lung cancers in clinical practice: Implications for future detection strategy and targeted therapy","volume":"10","author":"Liu","year":"2024","journal-title":"Heliyon"},{"key":"key20251205105345_b3-ol-31-1-15385","doi-asserted-by":"publisher","first-page":"612","DOI":"10.3390\/ijms22020612","article-title":"Molecular epidemiology of the main druggable genetic alterations in non-small cell lung cancer","volume":"22","author":"Fois","year":"2021","journal-title":"Int J Mol Sci"},{"key":"key20251205105345_b4-ol-31-1-15385","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.semcancer.2022.04.002","article-title":"EGFR signaling pathway as therapeutic target in human cancers","volume":"85","author":"Levantini","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"key20251205105345_b5-ol-31-1-15385","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"key20251205105345_b6-ol-31-1-15385","doi-asserted-by":"publisher","first-page":"1004198","DOI":"10.3389\/fonc.2022.1004198","article-title":"Meeting an un-MET need: Targeting MET in non-small cell lung cancer","volume":"12","author":"Michaels","year":"2022","journal-title":"Front Oncol"},{"key":"key20251205105345_b7-ol-31-1-15385","doi-asserted-by":"publisher","first-page":"101952","DOI":"10.1016\/j.eclinm.2023.101952","article-title":"Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: A multicentre, single-arm, open-label, phase 1b\/2 trial","volume":"59","author":"Yu","year":"2023","journal-title":"EClinicalMedicine"},{"key":"key20251205105345_b8-ol-31-1-15385","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41568-019-0179-8","article-title":"Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy","volume":"19","author":"Skoulidis","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"key20251205105345_b9-ol-31-1-15385","doi-asserted-by":"publisher","first-page":"bcr2013201554","DOI":"10.1136\/bcr-2013-201554","article-title":"The CARE guidelines: Consensus-based clinical case reporting guideline development","volume":"2013","author":"Gagnier","year":"2013","journal-title":"BMJ Case Rep"},{"key":"key20251205105345_b10-ol-31-1-15385","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC lung cancer staging project: Proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J Thorac Oncol"},{"key":"key20251205105345_b11-ol-31-1-15385","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the eastern cooperative oncology group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"key20251205105345_b12-ol-31-1-15385","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.annonc.2025.04.003","article-title":"Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and\/or amplification following disease progression on osimertinib: Primary results from the phase II SAVANNAH study","volume":"36","author":"de Marinis","year":"2025","journal-title":"Ann Oncol"},{"key":"key20251205105345_b13-ol-31-1-15385","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.jtho.2018.04.034","article-title":"Revised modified response evaluation criteria in solid tumors for assessment of response in malignant pleural mesothelioma (version 1.1)","volume":"13","author":"Armato","year":"2018","journal-title":"J Thorac Oncol"},{"key":"key20251205105345_b14-ol-31-1-15385","doi-asserted-by":"publisher","first-page":"e20636","DOI":"10.1200\/JCO.2017.35.15_suppl.e20636","article-title":"Coexistence of MET exon 14 mutations with EGFR mutations in non-small cell lung cancer","volume":"35","author":"Li","year":"2017","journal-title":"J Clin Oncol"},{"key":"key20251205105345_b15-ol-31-1-15385","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br J Cancer"},{"key":"key20251205105345_b16-ol-31-1-15385","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.cllc.2023.06.008","article-title":"MET exon 14 skipping in NSCLC: A systematic literature review of epidemiology, clinical characteristics, and outcomes","volume":"24","author":"Mazieres","year":"2023","journal-title":"Clin Lung Cancer"},{"key":"key20251205105345_b17-ol-31-1-15385","doi-asserted-by":"publisher","first-page":"100347","DOI":"10.1016\/j.esmoop.2021.100347","article-title":"Molecular characterization and clinical outcomes in EGFR-mutant de novo MET-overexpressed advanced non-small-cell lung cancer","volume":"7","author":"Mi","year":"2022","journal-title":"ESMO Open"},{"key":"key20251205105345_b18-ol-31-1-15385","doi-asserted-by":"publisher","first-page":"e601","DOI":"10.1016\/j.cllc.2020.05.015","article-title":"Combining EGFR and MET inhibition with crizotinib in EGFR-mutated lung adenocarcinoma harboring MET amplification: A brief report","volume":"21","author":"Aubanel","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"key20251205105345_b19-ol-31-1-15385","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.cllc.2018.09.009","article-title":"Successful treatment of a patient with NSCLC harboring an EGFR mutation and a concomitant met exon 14 skipping mutation combining afatinib and crizotinib","volume":"20","author":"Kauffmann-Guerrero","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"key20251205105345_b20-ol-31-1-15385","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1158\/1535-7163.MCT-17-0368","article-title":"Preclinical evaluation of SCC244 (Glumetinib), a novel, potent, and highly selective inhibitor of c-Met in MET-dependent cancer models","volume":"17","author":"Ai","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"key20251205105345_b21-ol-31-1-15385","doi-asserted-by":"publisher","first-page":"761","DOI":"10.2147\/DDDT.S388846","article-title":"Effect of food on the pharmacokinetics and safety of a novel c-Met inhibitor SCC244: A randomized phase I study in healthy subjects","volume":"17","author":"Wu","year":"2023","journal-title":"Drug Des Devel Ther"},{"key":"key20251205105345_b22-ol-31-1-15385","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.cpt.2024.12.005","article-title":"Capmatinib treatment in a patient with osimertinib-resistant NSCLC harboring two distinct MET alterations revealed by tissue-based NGS testing","volume":"3","author":"Lausoontornsiri","year":"2024","journal-title":"Cancer Pathog Ther"},{"key":"key20251205105345_b23-ol-31-1-15385","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.cllc.2024.11.014","article-title":"Brief report: Osimertinib Plus capmatinib for patients with MET-altered EGFR-mutant NSCLC following progression on front line therapy","volume":"26","author":"Elghawy","year":"2025","journal-title":"Clin Lung Cancer"},{"key":"key20251205105345_b24-ol-31-1-15385","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/MCP.0000000000000778","article-title":"The evolving paradigm of precision medicine in lung cancer","volume":"27","author":"Passiglia","year":"2021","journal-title":"Curr Opin Pulm Med"},{"key":"key20251205105345_b25-ol-31-1-15385","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41571-022-00700-7","article-title":"Barriers in access to oncology drugs-a global crisis","volume":"20","author":"Barrios","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"key20251205105345_b26-ol-31-1-15385","first-page":"1","article-title":"Barriers to access: Global variability in implementing treatment advances in lung cancer","volume":"42","author":"Febbraro","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"key20251205105345_b27-ol-31-1-15385","doi-asserted-by":"publisher","first-page":"e324","DOI":"10.1093\/oncolo\/oyad020","article-title":"Implementation of precision oncology in clinical practice: Results of a national survey for health care professionals","volume":"28","author":"Fasola","year":"2023","journal-title":"Oncologist"},{"key":"key20251205105345_b28-ol-31-1-15385","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13045-019-0759-9","article-title":"MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer","volume":"12","author":"Wang","year":"2019","journal-title":"J Hematol Oncol"},{"year":"2021","key":"key20251205105345_b29-ol-31-1-15385","article-title":"A Multicenter, Randomized, Double-blind, Phase III Clinical Study to Evaluate the Efficacy and Safety of Savolitinib + Osimertinib Versus Placebo + Osimertinib as the First Line Therapy for Patients With EGFRm+\/MET+ NSCLC"},{"year":"2021","key":"key20251205105345_b30-ol-31-1-15385","article-title":"A Prospective, Pilot Study of First-line Osimertinib With or Without Savolitinib in de Novo MET Positive, EGFR-mutant NSCLCs (FLOWERS)"},{"year":"2020","key":"key20251205105345_b31-ol-31-1-15385","article-title":"A Multi-centre Phase II, Double-Blind, Randomised Study of Savolitinib in Combination With Osimertinib vs Savolitinib in Combination With Placebo in Patients With EGFRm+ and MET Amplified Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed Following Treatment With Osimertinib"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T08:53:54Z","timestamp":1764924834000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2025.15385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,11,12]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2025.15385","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"type":"print","value":"1792-1074"},{"type":"electronic","value":"1792-1082"}],"subject":[],"published":{"date-parts":[[2025,11,12]]}}}